Climb Bio (CLYM) Enterprise Value (2021 - 2026)

Climb Bio (CLYM) has 7 years of Enterprise Value data on file, last reported at -$109.6 million in Q1 2026.

• Quarterly Enterprise Value fell 11.73% year-over-year to -$109.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$109.6 million (down 11.73% YoY) and the FY2025 annual result came in at -$101.1 million, up 33.02% from the prior year.
• Enterprise Value eased to -$109.6 million in Q1 2026, from -$101.1 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$84.7 million in Q2 2025 to a low of -$261.7 million in Q3 2024.
• A 5-year average of -$130.8 million and a median of -$109.6 million in 2026 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2024 — Enterprise Value slumped 143.6% — and 2025, when it jumped 66.79%.
• Tracing CLYM's Enterprise Value over 5 years: stood at -$123.6 million in 2022, then gained by 5.66% to -$116.6 million in 2023, then declined by 29.47% to -$150.9 million in 2024, then surged by 33.02% to -$101.1 million in 2025, then slipped by 8.39% to -$109.6 million in 2026.
• The last three Enterprise Value figures came in at -$109.6 million (Q1 2026), -$101.1 million (Q4 2025), and -$86.9 million (Q3 2025), per Business Quant data.